Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...

you should consider Globus Medical (GMED). This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat. This medical device company has seen a ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...

周一，Jefferies分析师Matthew Taylor调整了Nevro Corp (NYSE: NVRO )的股票评级，从"减持"上调至"持有"。同时，目标价也从此前的$4.50上调至$5.85。这一调整是在Nevro最近宣布被GMED收购后做出的，Taylor对GMED持积极态度。目前，Nevro股价报$5.72，过去一周强劲上涨14.86%。根据 InvestingPro ...

周四，Canaccord Genuity维持Globus Medical (NYSE: GMED )的买入评级，目标价为101.00美元。该公司目前股价为88.54美元。该机构的分析支持公司当前战略，特别是在收购Nevro Corp之后。Canaccord Genuity对Globus ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected ...